- cafead   Dec 04, 2023 at 06:33: PM
via After heralding data last month showing that the multiple sclerosis candidate fenebrutinib may have crossed the blood-brain barrier, Genentech revealed quietly last week that the program has been placed on a partial clinical hold by the FDA in the U.S.
article source
article source